Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS) - Wikidata - wikimedia - TriplyDB

Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)

Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)

http://www.wikidata.org/entity/Q35483580

about

Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.Simultaneous Manifestation of Chronic Myelomonocytic Leukemia and Multiple Myeloma during Treatment by Prednisolone and Eltrombopag for Immune-Mediated Thrombocytopenic Purpura.The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.Simultaneous occurrence of two B-cell malignancies: A case report.Lenalidomide in multiple myeloma: current experimental and clinical data.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Lenalidomide after stem-cell transplantation for multiple myeloma Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups.Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.Unusual case of simultaneous presentation of plasma cell myeloma, chronic myelogenous leukemia, and a jak2 positive myeloproliferative disorder.Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells.Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.New cancers after autotransplantations for multiple myeloma.Second malignancies after multiple myeloma: from 1960s to 2010s.Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?Autopsy Analysis may Contribute to Establish Actual Incidence of Second Primary Malignancies in Myeloma.Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma.Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics Time trend of multiple myeloma and associated secondary primary malignancies in Asian patients: a Taiwan population-based study.The Incidence of Senile Cataract and Glaucoma is Increased in Patients with Plasma Cell Dyscrasias: Etiologic Implications.Secondary lymphoblastic leukemia occurring 38 months after the primary diagnosis of multiple myeloma: A case report.Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.Search for familial clustering of cancer in monoclonal gammopathy of unknown significance.Update on second primary malignancies in multiple myeloma: a focused review.The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.Maintenance therapy in newly diagnosed multiple myeloma: current recommendations.Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.The risk of secondary primary malignancies after therapy for multiple myeloma.An update on the use of lenalidomide for the treatment of multiple myeloma.Immunologic approaches for the treatment of multiple myeloma.Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance.Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects.Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

P2860

Q27851694-628C50F1-B245-4EB5-9D2C-C6829185D17A Q30538788-F2F6F648-E27C-431F-A87A-54CAF5CC46F5 Q33435162-56EC9684-6808-4D96-90F3-8079DB50DCC4 Q33695919-DB760726-C244-4402-9A79-F51D225B5C62 Q33802749-F0ABC83D-C1E5-4696-A505-A31A70EF948C Q33844150-E73C10A7-DE0A-4AA0-A50D-8F9A51519B01 Q34074803-664F51A0-6DD0-4D88-ACC4-04E701781D6E Q34253548-E2BF2D6F-7B0A-4FF8-90DC-5545C16AF3F2 Q34273726-4B612DC8-F87B-4C76-A501-0544086B2B24 Q34283333-3A7AB386-5E3F-496E-905D-16214B00F762 Q34399099-BC2DF66F-2028-460D-8D88-63AD407639B4 Q34425602-12E0F686-11F6-496D-BBDA-26E6A42FC673 Q34652128-B7E1853D-C44B-47E0-976D-9F3FE835B2B9 Q34694749-220D8AE1-2855-4E55-90C1-2666122F6E82 Q34964597-E7C2B32D-7C09-412C-AB5A-55D4E2D69D0A Q35177465-CF4B486E-4A40-4C2C-8963-F046E780BD03 Q35891594-EEFF60BC-40A0-47A0-9E6B-E7859E78A015 Q36115686-EBB8E53E-2CF0-48B3-ABEB-DAB86D69946E Q36366988-EE0F6C22-F875-4FE4-9C86-EB5E68A5D866 Q36438206-331830F0-F59A-49B0-8870-ED6008836055 Q36557015-D72B262C-2446-4CC1-93BA-B91F3CE09539 Q36611288-39E42325-5750-4F23-81D3-075562C94E86 Q36912632-09E15366-A3AD-476F-9AD6-57DD146685C2 Q36973705-B95DBDA3-067B-4C8D-A7C8-90D2F7EDF00E Q36976375-4A755716-E364-434F-ACEF-E4B5BB7DA241 Q37027418-7CD6A31B-87F7-44BD-A0D5-459D1823A4D9 Q37108758-36A149F7-C806-4E01-A66F-BF0B13A45A68 Q37216305-4A141FAE-77B2-4412-AEF7-8141D0518A2C Q37228026-65F16284-9057-4DFB-A0D4-712F441AA490 Q37271011-D6638293-2C60-4CA0-A940-BAF8C2327BC9 Q38178031-316F7511-6AD6-4570-94B5-36D64139D225 Q38182679-77B40FF3-C6C5-44D0-B62D-E7C036548FAF Q38191975-E974980D-9D16-4DA8-A72C-3C7C52690BEA Q38371861-D99B2CF9-2FB5-4740-9B25-0018E015F848 Q38462594-2E4AD2CE-5E2B-42F3-9022-AEC1E46782C5 Q38545607-9CC6620F-6DF8-4376-A103-9536E94E25C0 Q38692244-F18E0151-D4AC-4AB1-A49E-3B2D8843BA5A Q38933428-D056FB11-F9F1-44A0-87C7-22F1AA1DB265 Q39013004-D55480CF-69E8-4EEB-B705-AB470F0278D6 Q39013620-220B5FD2-20D7-4CDC-8811-75DF2D9C3702

P2860

Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)

http://www.wikidata.org/entity/Q35483580

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Risk of acute myeloid leukemia ...... d its precursor disease (MGUS)

@ast

Risk of acute myeloid leukemia ...... d its precursor disease (MGUS)

@en

type

label

Risk of acute myeloid leukemia ...... d its precursor disease (MGUS)

@ast

Risk of acute myeloid leukemia ...... d its precursor disease (MGUS)

@en

prefLabel

Risk of acute myeloid leukemia ...... d its precursor disease (MGUS)

@ast

Risk of acute myeloid leukemia ...... d its precursor disease (MGUS)

@en

P1433

Q35483580-ED0BEC54-14EC-4B9D-9C0F-BA3AE3C0417E

P1476

Q35483580-5329DC36-ADBA-49D9-9D9D-F99F0EDAE7F5

P2093

Q35483580-00A61F44-00BA-41F2-999D-2B1E32BA3A2E

Q35483580-26DF48C3-CAFE-4739-9683-324689293E6D

Q35483580-2A925F79-0787-4AE5-B573-7952AA5B5391

Q35483580-3E47C785-5997-45DC-A9F5-F99E73A8993D

Q35483580-7869D5CA-09D3-4AFC-86A1-4FCD320065DE

Q35483580-8EAD8B36-4BCE-4092-948E-B8604F0A1554

Q35483580-9C6933FB-A8F7-4B87-8F9F-4475DA30DE0F

P2860

Q35483580-01CFAF5E-F12E-4C58-A753-A9A1A2ED622C

Q35483580-0AF3832D-32B2-4DC2-A9BF-67ED86461891

Q35483580-0ECCCFB2-3F3D-48B9-B125-5C3F471C7578

Q35483580-19E7B2B4-A63E-4197-B26C-B3AFBC0448AF

Q35483580-27A540A8-9AC7-4D63-A5E2-BBAE4EF9CC55

Q35483580-2CC3BF3D-04F2-4908-BFF3-6470E5E67381

Q35483580-370B50DE-967F-40EC-BA65-280BC02ACAC5

Q35483580-40D3994D-ABCC-414D-8D91-72648910A68D

Q35483580-56967FA7-8231-4557-83FC-C741E62A199E

Q35483580-61493AF4-EEE1-4DC4-8B65-67B8E747FD1F

P304

Q35483580-642FAA34-1CCE-4734-86AB-5A59E3565430

P31

Q35483580-928E013C-7792-4996-B7B2-43A69ADFFDA1

P356

Q35483580-AD4B3C16-2549-469E-BFCD-EE9FB8DF6400

P407

Q35483580-E9BAD6C0-B824-4C98-9654-DFFAA9CD5BD6

P433

Q35483580-327A1E58-1802-4328-8869-9725A2046986

P478

Q35483580-A67793EB-B10C-4813-BA46-0E281E81AD65

P50

Q35483580-9D27335C-797E-4ED8-99B5-1A416416D782

P577

Q35483580-C8ABA874-F907-4E2C-A107-24EEB58F50BC

P5875

Q35483580-82EC3B7D-8C1C-4356-A8C4-5DEAD7F547E4

P698

Q35483580-3F8690E5-C1F6-4051-8675-8F9B75B73304

P921

Q35483580-7ED28121-FD7B-4F91-BC57-CC1030DB390A

P932

Q35483580-F542F67C-4E8B-4415-A0A5-A2DBBA86D029

P356

BLOOD-2011-05-355743

P1433

P1476

Risk of acute myeloid leukemia ...... d its precursor disease (MGUS)

@en

P2093

Ingemar Turesson

http://www.w3.org/2001/XMLSchema#string

Lynn R Goldin

http://www.w3.org/2001/XMLSchema#string

Magnus Bjorkholm

http://www.w3.org/2001/XMLSchema#string

Neha Korde

http://www.w3.org/2001/XMLSchema#string

Ruth M Pfeiffer

http://www.w3.org/2001/XMLSchema#string

Sham Mailankody

http://www.w3.org/2001/XMLSchema#string

Sigurdur Y Kristinsson

http://www.w3.org/2001/XMLSchema#string

P2860

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

Cancer statistics, 2010

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study

Antitumor activity of thalidomide in refractory multiple myeloma.

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Prevalence of monoclonal gammopathy of undetermined significance.

A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults

P304

4086-4092

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-05-355743

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51527296

http://www.w3.org/2001/XMLSchema#string

P698

21795746

http://www.w3.org/2001/XMLSchema#string

P921

P932

3204729

http://www.w3.org/2001/XMLSchema#string